All In Biotech

Drug Trial Radar · NCT06084884

A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma

A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent Hepatocellular Carcinoma: ATHENA

Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

94

Planned (sponsor's estimate)

Start

Dec 14, 2023

Primary completion

Dec 13, 2027

Study completion Dec 13, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 16, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase I/II study to evaluate AZD5851 in patients with GPC3+ advanced/recurrent hepatocellular carcinoma.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • AZD5851Biological

    Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce AZD5851. During AZD5851 production, subjects may receive bridging therapy for disease control. Upon successful generation of AZD5851 product, subjects will receive treatment with AZD5851 therapy. Study treatment will include lymphodepleting chemotherapy followed by one dose of AZD5851 administered by intravenous (IV) infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1. Incidence of participants with dose-limiting toxicities (DLTs), adverse events (AEs), including adverse events of special interest (AESI) and serious adverse events (SAEs). Determination of the recommended dose of AZD5851 for expansion phaseTime frame: Through study completion, an average of 2 years

Locations

19 sites in 3 countries. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona

  • Research Site

    Duarte, California

  • Research Site

    Los Angeles, California

  • Research Site

    Orange, California

  • Research Site

    San Francisco, California

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Jacksonville, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Westwood, Kansas

  • Research Site

    Rochester, Minnesota

  • Research Site

    Hackensack, New Jersey

  • Research Site

    New York, New York

  • Research Site

    Columbus, Ohio

  • Research Site

    Portland, Oregon

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Kashiwa, Japan

  • Research Site

    Osakasayama-shi, Japan

  • Research Site

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.